Skip to main content

Scientists Discover Way to Send Information into Black Holes Without Using Energy

3 comments

A Historic Breakthrough: WHO Approves First Malaria Treatment Designed for Infants

In a major step forward for global health, the World Health Organization (WHO) has approved the first-ever malaria treatment specifically designed for newborns and infants. This decision marks a turning point in the fight against one of the world’s deadliest diseases, especially for the most vulnerable—young children.

Malaria has long been a serious global health challenge, claiming hundreds of thousands of lives each year. While treatments have existed for decades, they were never tailored for babies. Until now, doctors had to rely on medicines designed for older children, which often came with risks. The newly approved drug, Artemether-lumefantrine, changes that reality by offering a safer and more accurate solution for infants.

Why This Approval Matters

Malaria is caused by parasites transmitted through the bites of infected mosquitoes. It disproportionately affects people living in tropical and subtropical regions, especially in Africa. Children under five years old are the most vulnerable group, accounting for the majority of malaria-related deaths.

Until this breakthrough, infants were treated with modified doses of medicines intended for older children. This approach was far from ideal. It increased the chances of dosing errors, side effects, and even toxicity. Babies are not just “small adults”—their bodies process medicines differently, and they require carefully designed formulations.

The WHO’s approval of an infant-specific treatment means healthcare providers can now deliver precise doses that are safer and more effective. This alone has the potential to save countless lives.

What Is Artemether-Lumefantrine?

Artemether-lumefantrine is a combination therapy widely used to treat malaria. It works by targeting the malaria parasite at different stages of its life cycle, making it highly effective in clearing infections.

What makes this new formulation special is that it has been specifically designed for newborns and infants. This includes adjustments in dosage strength, tablet size, and formulation to ensure it can be safely administered to very young children.

The WHO granted it “prequalification” status, which means the medicine has met strict international standards for quality, safety, and effectiveness. This designation is crucial because it allows global organizations and governments to procure and distribute the drug with confidence.

The Global Burden of Malaria

Despite decades of efforts, malaria continues to pose a major health threat. According to WHO estimates, there were around 282 million malaria cases and 610,000 deaths worldwide in 2024. These numbers highlight how persistent and widespread the disease remains.

Africa bears the heaviest burden, accounting for about 95% of all malaria cases and deaths. Within this region, children under five represent the most affected group, contributing to nearly three-quarters of all malaria-related deaths.

For families in malaria-endemic areas, the disease is more than a health issue—it is a cycle that impacts education, economic stability, and overall well-being. Frequent illness can prevent children from attending school and adults from working, deepening poverty in already vulnerable communities.

A Long-Standing Treatment Gap

Every year, around 30 million babies are born in regions where malaria is common. Yet until now, there was no treatment specifically approved for this age group. This created a significant gap in healthcare systems.

The WHO’s prequalification of Artemether-lumefantrine is expected to close this gap. It will enable public health programs to procure and distribute the drug more widely, ensuring that even the youngest patients receive appropriate care.

This move also sends a strong message to pharmaceutical companies and researchers: there is an urgent need to develop treatments tailored for all age groups, including those often overlooked.

Challenges Still Remain

While this development is promising, the fight against malaria is far from over. Several challenges continue to slow progress:

1. Drug Resistance:
Malaria parasites are evolving and becoming resistant to existing treatments. This makes it harder to control the disease and increases the need for new medicines.

2. Insecticide Resistance:
Mosquitoes are also adapting, becoming resistant to the chemicals used in insecticide-treated nets and sprays.

3. Diagnostic Limitations:
In some regions, malaria tests may fail to detect infections accurately, leading to delayed or incorrect treatment.

4. Funding Gaps:
A significant reduction in international aid has affected malaria prevention and treatment programs, especially in low-income countries.

5. Weak Regulatory Systems:
Globally, about 70% of countries lack strong systems to regulate medicines, vaccines, and medical devices. This makes it difficult to ensure that only safe and effective products reach patients.

The Role of WHO Prequalification

The WHO prequalification program plays a critical role in addressing these challenges. It ensures that health products used in global programs meet high standards of quality, safety, and performance.

For countries with limited regulatory capacity, this program acts as a trusted benchmark. Governments and international organizations can rely on WHO-approved products without having to conduct their own extensive evaluations.

By granting prequalification to the infant formulation of Artemether-lumefantrine, the WHO has paved the way for faster and wider access to this life-saving treatment.

A Broader Fight Against Malaria

This breakthrough is part of a larger effort to combat malaria using multiple strategies. In recent years, significant progress has been made through:

  • The development of malaria vaccines

  • Improved diagnostic tools

  • Next-generation mosquito nets

  • Enhanced public health campaigns

Together, these innovations are helping to reduce the impact of malaria and move closer to long-term control—and eventually elimination.

WHO Director-General Tedros Adhanom Ghebreyesus emphasized this progress, stating that the fight against malaria is entering a new phase. With the right commitment and resources, ending malaria within our lifetime is becoming a realistic goal.

Looking Ahead: Hope for the Future

The approval of the first malaria treatment specifically for infants is more than just a medical milestone—it is a symbol of progress and hope. It shows that global health efforts are evolving to address the needs of even the most vulnerable populations.

However, innovation alone is not enough. Sustained political will, increased funding, and stronger healthcare systems are essential to ensure that these advances reach the people who need them most.

If governments, organizations, and communities continue to work together, the dream of a malaria-free world may finally come within reach.

Conclusion

The WHO’s approval of an infant-specific malaria treatment marks a historic moment in global health. By addressing a long-standing gap in care, this breakthrough has the potential to save millions of young lives.

While challenges remain, this development proves that progress is possible. With continued effort, investment, and innovation, the fight against malaria can move from control to elimination—bringing us closer to a future where no child dies from a preventable disease.


Comments

Post a Comment

Popular

Scientists Discover Way to Send Information into Black Holes Without Using Energy

For years, scientists believed that adding even one qubit (a unit of quantum information) to a black hole needed energy. This was based on the idea that a black hole’s entropy must increase with more information, which means it must gain energy. But a new study by Jonah Kudler-Flam and Geoff Penington changes that thinking. They found that quantum information can be teleported into a black hole without adding energy or increasing entropy . This works through a process called black hole decoherence , where “soft” radiation — very low-energy signals — carry information into the black hole. In their method, the qubit enters the black hole while a new pair of entangled particles (like Hawking radiation) is created. This keeps the total information balanced, so there's no violation of the laws of physics. The energy cost only shows up when information is erased from the outside — these are called zerobits . According to Landauer’s principle, erasing information always needs energy. But ...
3 comments
Read more

Black Holes That Never Dies

Black holes are powerful objects in space with gravity so strong that nothing can escape them. In the 1970s, Stephen Hawking showed that black holes can slowly lose energy by giving off tiny particles. This process is called Hawking radiation . Over time, the black hole gets smaller and hotter, and in the end, it disappears completely. But new research by Menezes and his team shows something different. Using a theory called Loop Quantum Gravity (LQG) , they studied black holes with quantum corrections. In their model, the black hole does not vanish completely. Instead, it stops shrinking when it reaches a very small size. This leftover is called a black hole remnant . They also studied something called grey-body factors , which affect how much energy escapes from a black hole. Their findings show that the black hole cools down and stops losing mass once it reaches a minimum mass . This new model removes the idea of a “singularity” at the center of the black hole and gives us a better ...
Post a Comment
Read more

How Planetary Movements Might Explain Sunspot Cycles and Solar Phenomena

Sunspots, dark patches on the Sun's surface, follow a cycle of increasing and decreasing activity every 11 years. For years, scientists have relied on the dynamo model to explain this cycle. According to this model, the Sun's magnetic field is generated by the movement of plasma and the Sun's rotation. However, this model does not fully explain why the sunspot cycle is sometimes unpredictable. Lauri Jetsu, a researcher, has proposed a new approach. Jetsu’s analysis, using a method called the Discrete Chi-square Method (DCM), suggests that planetary movements, especially those of Earth, Jupiter, and Mercury, play a key role in driving the sunspot cycle. His theory focuses on Flux Transfer Events (FTEs), where the magnetic fields of these planets interact with the Sun’s magnetic field. These interactions could create the sunspots and explain other solar phenomena like the Sun’s magnetic polarity reversing every 11 years. The Sun, our closest star, has been a subject of scient...
Post a Comment
Read more